3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
No longer available
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, B-Cell
3
Lymphoma
3
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Recurrence
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Cyclophosphamide
23
venetoclax
17
Dexamethasone
16
pembrolizumab
15
fludarabine
15
Cytarabine
13
pomalidomide
8
Rituximab
8
Gemcitabine
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
selinexor
6
Paclitaxel
6
Injections
6
Immunotherapy, Adoptive
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Oxaliplatin
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
loncastuximab tesirine
×
Clear all
NCT06918912
2025-04-09
LORELY
Istituto Clinico Humanitas
Phase 2
Recruiting
50 enrolled